Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
The Journal of International Medical Research|October 26, 2001
Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertensionM Hanefeld, C Abletshauser
Biosensors & Bioelectronics|April 23, 2003
The effect of an HMG-CoA reductase inhibitor on arteriosclerotic nanoplaque formation and size in a biosensor modelG Siegel, C Abletshauser, M Malmsten, et al.
Cardiovascular Research|June 12, 2003
Reduction of arteriosclerotic nanoplaque formation and size by fluvastatin in a receptor-based biosensor modelG Siegel, C Abletshauser, M Malmsten, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 29, 2007
Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokineticsG Fauler, C Abletshauser, W Erwa, et al.
Atherosclerosis|June 25, 1999
A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart diseaseG Rothe, A S Herr, J Stöhr, et al.
Atherosclerosis|June 25, 1999
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatmentG Riegger, C Abletshauser, M Ludwig, et al.
Thrombosis Research|October 9, 1999
Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitorG Huhle, C Abletshauser, N Mayer, et al.
Acta Physiologica Scandinavica|October 2, 2002
Biosensing of arteriosclerotic nanoplaque formation and interaction with an HMG-CoA reductase inhibitorC Abletshauser, D Klüssendorf, A Schmidt, et al.
European Journal of Clinical Pharmacology|January 1, 1997
Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metalsW Leonhardt, T Kurktschiev, D Meissner, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 22, 2005
Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomographyF M Bengel, C Abletshauser, J Neverve, et al.
Pageof 2